The first successful pancreatoduodenectomy was performed as a 2-stage procedure by Walter Kausch in 1909.^[@R1]^ Later, Allen O. Whipple popularized the procedure by a series of 37 pancreatoduodenectomies during his career.^[@R2]^ Because of high mortality, the operation was nearly abandoned in the 1970s.^[@R2]^ In the 1990s, large retrospective series from specialized centers around the world set a benchmark for operative mortality of below 5%.^[@R2]^ Nevertheless, morbidity remains substantial after pancreatoduodenectomy.^[@R3]--[@R10]^ The main contributing factor is postoperative pancreatic fistula (POPF), involving leakage of pancreatic juice from the pancreatic anastomosis, which can lead to severe secondary complications such as intra-abdominal abscesses and erosion bleeding.^[@R9],[@R11],[@R12]^ Data regarding the prevention of POPF by application of somatostatin analogues have been controversial thus far,^[@R13],[@R14]^ but a recent randomized trial strongly suggests that pasireotide successfully reduces POPF rates.^[@R15]^ Numerous attempts at improving pancreatic anastomosis techniques to lower POPF rates have been proposed.^[@R2],[@R16],[@R17]^ The hypothesis of this trial dates back to Walter Kausch, who discussed the possibility of anastomosis of the pancreatic remnant to the jejunum (pancreatojejunostomy, PJ) or the stomach (pancreatogastrostomy, PG) in his 1912 original publication of the first successful pancreatoduodenectomy.^[@R1]^

Almost all retrospective studies suggest superiority of PG over PJ in terms of reduced POPF and other complications.^[@R18]^ To date, however, conflicting results have been reported from 8 prospective randomized controlled trials (RCTs) published from 1995 to 2014^[@R19]--[@R26]^ (see Supplemental Digital Content Table S1, available at): Only 3 RCTs^[@R22],[@R24],[@R25]^ have demonstrated a reduced rate of POPF after PG, and 4 RCTs^[@R20],[@R22],[@R24],[@R25]^ found advantages of PG over PJ in terms of postoperative complications. Soft pancreatic texture was identified as a risk factor for POPF and other complications in 4 RCTs.^[@R19],[@R21],[@R23],[@R25]^ However, the available RCTs have some limitations. With the exception of the recent Belgian multicenter RCT^[@R24]^ including 329 patients, total case numbers of the RCTs are relatively low (n = 90--151) and only 2 RCTs are multicenter trials. Definitions of perioperative outcomes vary as early trials did not use the current consensus definitions of specific complications in pancreatic surgery established by the International Study Group for Pancreatic Surgery (ISGPS). Although many technical variations of PG and PJ have been reported,^[@R16],[@R17]^ all 8 RCTs were restricted to specific subtypes of PG and PJ. Only 2 RCTs with contradictory results report on postoperative pancreatic function measured during follow-up of 3 to 12 months: the Egyptian trial^[@R26]^ reports worse and the Spanish trial^[@R25]^ reports better pancreatic function. None of the RCTs report on quality of life during follow-up.

Here we present data collected at 14 high-volume centers for pancreatic surgery in Germany from the currently largest multicenter randomized trial comparing PG with PJ with respect to perioperative complications and long-term pancreatic function and quality of life.

PATIENTS AND METHODS
====================

Study Design, Hypothesis, and Inclusion Criteria
------------------------------------------------

The RECOnstruction after PANCreatoduodenectomy Study (RECOPANC) was designed as a randomized, controlled, observer- and patient-blinded multicenter trial with 2 parallel treatment arms (PG and PJ) (see Supplemental Digital Content, available at). The hypothesis was that the rate of clinically relevant POPF is lower after PG. Inclusion criteria were planned pancreatoduodenectomy at one of the participating academic centers and age more than 18 years. Exclusion criteria were participation in interfering clinical trials and expected lack of compliance. With the rationale to increase willingness of participating surgeons to recruit patients and to achieve greater generalizability of the results, we did not restrict PG or PJ to a special technique. Fourteen German academic centers (RECOPANC Trial Group^[@R27]^) with a median case load of 78 major pancreatic resections per year (range: 29--499, figures for year 2012 from the Association of German University Clinics, [http://www.uniklinika.de](http://www.uniklinika.de/)) participated in the trial.

Primary Endpoint and Sample Size
--------------------------------

POPF is defined by ISGPS as the occurrence of amylase activity in abdominal drain fluid of 3 times the upper serum limit on postoperative day 3 or later.^[@R28],[@R29]^ In brief, grade A fistula is self-limited and does not need specific treatment, grade B requires medical or invasive interventional treatment, and grade C leads to reoperation and/or severe secondary complications. The primary endpoint chosen for this trial was clinically relevant POPF, that is, ISGPS grade B or C, with the modification that application of somatostatin analogues was not considered a criterion for grading. The primary endpoint was assessed on postoperative day 3 at hospital discharge and on postoperative day 30 to detect all POPFs.

Based on the prior assumption of a POPF B/C rate of 6% and 16% with PG and PJ, respectively, α = 5% and β = 20%, a sample size of 153 per treatment arm (PG vs PJ) was calculated with the 2-sided χ^2^ test. An adaptive interim analysis of the primary endpoint according to Bauer and Koehne^[@R30]^ was planned after recruitment of 152 patients to allow for premature trial termination (with 1-sided stopping boundaries of *P* \< 0.0038) and sample size recalculation.

Secondary Endpoints and Follow-up
---------------------------------

Secondary surgical endpoints were death, relaparotomy, completion pancreatectomy, anastomotic leak other than pancreatic fistula, wound infection, delayed gastric emptying, postpancreatectomy hemorrhage according to the ISGPS definitions,^[@R31],[@R32]^ intra-abdominal abscess requiring invasive treatment, operation time (skin incision to skin closure), and postoperative hospital stay. Further secondary endpoints included septic shock, respiratory failure, deep venous thrombosis, lung embolism, myocardial infarction, and stroke. Pancreatic endocrine and exocrine functions and quality of life were evaluated in long-term follow-up at baseline, 6 and 12 months after the operation by the validated European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ) C30 and the pancreatic cancer module PAN26.^[@R33],[@R34]^

Randomization and Blinding
--------------------------

Center-based block randomization was performed by the participating centers using a centralized Web-based tool (Randomizer Software, Institute for Medical Informatics, Statistics and Documentation of the Medical University of Graz, www.randomizer.at) with allocation concealment. To avoid a possible intraoperative selection of low-risk patients,^[@R23]^ randomization was performed preoperatively. Obviously, the surgeons were not blinded concerning the intervention. Therefore, blinded observers at the participating centers assessed the primary endpoint. Patients were kept blinded regarding the intervention and unblinded only in the case of emergencies where necessary.

Ethical Approval, Safety, and Registration
------------------------------------------

The study protocol was approved by the local ethics committees of the participating centers and carried out according to the rules of Good Clinical Practice and the Declaration of Helsinki.^[@R35]^ Written informed consent was obtained from each patient. An independent institution served as the Data Safety Monitoring Board and was responsible for on-site clinical monitoring, source data verification, and management of severe adverse event reports (Center for Clinical Studies, Freiburg, Germany). The trial was assigned a Universal Trial Number (UTN U1111-1117-9588) and registered in the German Trials Register (DRKS 00000767) on March 23, 2011. The study protocol was published in *Trials*.^[@R27]^

Statistical Analysis
--------------------

The primary endpoint was analyzed according to the intention-to-treat principle (see Supplemental Digital Content, available at). A multivariate logistic regression model adjusting a priori for age, center, surgeon volume/experience, and pancreatic texture was applied to compare POPF rates in both treatment groups. Missing values for the primary endpoint were replaced by imputed case analysis according to Higgins et al.^[@R36]^ Exploratory analysis was planned for secondary endpoints. SAS software 9.1 (SAS 9.1 software, SAS, Cary NC) and 2-sided tests were used for all calculations.

RESULTS
=======

Trial Flow
----------

A total of 618 patients were screened and 440 patients were randomized from May 31, 2011, through December 5, 2012. The number of patients randomized per center is shown in Supplemental Digital Content Fig. S1, available at, and ranged from 6 to 84, with 5 centers recruiting less than 20 patients and 2 centers recruiting more than 50 patients. After the interim analysis of the first 152 included patients, the Data Safety and Monitoring Board advised continuation of the trial. A total of 120 randomized patients were excluded from the final analysis: 3 patients were randomized by mistake (randomized but not eligible), 5 did not undergo laparotomy, and 112 did not receive pancreatoduodenectomy and were, therefore, excluded from further analysis. Fifteen patients randomized to PG received PJ and 12 patients randomized to PG received PJ because of the surgeon\'s technical preference. Reasons given for PJ instead of PG included technical problems with PG: short pancreatic remnant (n = 9), difficult pancreatic remnant mobilization (n = 2), and gastric ulcer (n = 1); reasons for PG instead of PJ were soft pancreas with small duct (n = 11) and pancreas divisum (n = 1). In total, 320 patients were included in the intention-to-treat analysis of the primary endpoint: 149 patients randomized for PJ and 171 randomized for PG. Ninety-six patients did not finish the whole 12-month follow-up because of prior death (n = 75), loss to follow-up (n = 10), withdrawal of consent (n = 5), and other reasons (n = 6) (Fig. [1](#F1){ref-type="fig"}).

![Trial flow chart. ITT indicates intention to treat; PP, per protocol.](ansu-263-440-g001){#F1}

Patient Baseline Characteristics and Operations
-----------------------------------------------

Patient baseline parameters are shown in Table [1](#T1){ref-type="table"}. The treatment groups were balanced in terms of age, sex, body mass index, indications, symptoms, preoperative biliary drainage, comorbidities, American Society of Anesthesiologists (ASA) Classification, medication, and standard laboratory parameters. The treatment groups were also comparable in terms of operation technique, surgeon experience/volume, and blood loss/intraoperative transfusion requirement. In particular, the rates of soft pancreata (PG vs PJ, 59% vs 57%) and nondilated pancreatic ducts (PG vs PJ, 58% vs 55%), which are indicators for increased risk of fistula formation,^[@R5],[@R37]--[@R40]^ were not significantly different between the 2 groups (Table [1](#T1){ref-type="table"}).

Supplemental Digital Content Table S2, available at, shows the technical varieties used for PG and PJ at the trial centers. According to the ISGPS classification for pancreatic anastomoses,^[@R16]^ the most commonly performed techniques were nonstented duct-mucosa anastomosis (ISGPS type I-A-S0) with 2 interrupted monofilament resorbable suture rows for PJ and nonstented dunking PG (ISGPS type II-B-S0) anastomosis with purse-string plus interrupted monofilament resorbable suture.

Primary Endpoint Analysis
-------------------------

The rate of clinically relevant POPF was 20% after PG and 22% after PJ in the control group (*P* = 0.62, 2-sided χ^2^ test, Table [2](#T2){ref-type="table"}). In a multivariate logistic regression model (Table [2](#T2){ref-type="table"}), including anastomotic technique (PG vs PJ), age, center (north vs south), pancreatic texture (soft vs hard) and surgeon volume (pancreatic resections per year), and soft pancreatic texture was the only significant factor affecting POPF B/C, with an odds ratio estimate of 2.1 (*P* = 0.016) (Table [2](#T2){ref-type="table"}).

As there were 12 patients allocated to PG receiving PJ instead and 15 patients with PG instead of PJ, we also performed an as-treated analysis of the primary endpoint (see Supplemental Digital Content Table S3, available at). The results did not differ from those of the intention-to-treat analysis.

Assessment of Learning Effects
------------------------------

The odds ratio estimate for fistula rate in surgeons with less than 10 pancreatoduodenectomies was 1.2 to 6.8 (95% confidence interval) but did not reach the significance level (*P* = 0.064 in multivariate analysis, see Table [2](#T2){ref-type="table"}). Surgeons with less than 10 pancreatoduodenectomies per year had a higher fistula rate with PJ (46%) than with PG (27%), and this effect was gradually lost with increasing individual case load (see Supplemental Digital Content Table S4, available at); however, these differences did not reach statistical significance. There was also no significant center effect as to the preferred type of anastomosis in the participating centers (see Supplemental Digital Content Table S4, available at).

Perioperative Secondary Endpoint Analysis
-----------------------------------------

Operation time did not differ between PG and PJ. There were no significant differences between PG and PJ with regard to the frequency of surgical complications such as delayed gastric emptying, intra-abdominal abscesses, relaparotomy, completion pancreatectomy, anastomotic leaks, and surgical site infection. There was also no difference in the incidence of systemic complications such as septic shock, respiratory failure, deep vein thrombosis, lung embolism, and myocardial infarction. There were more (n = 5) stroke events in the PG group but none in the PJ group (*P* = 0.035) and significantly more postpancreatectomy hemorrhage events in the PG group (*P* = 0.023), the latter due to more grade A (5% vs 1%) and B (9% vs 4%) hemorrhages. Stroke and grade A/B bleeding were not associated, however (*P* = 0.998). Perioperative in-house mortality in the treatment groups (PG vs PJ, 6% vs 5%, *P* = 0.963) and 90-day mortality (PG vs PJ, 10% vs 5%, *P* = 0.167) were not statistically different. Postoperative hospital stay was equal with a median of 16 days (Table [3](#T3){ref-type="table"}).

Survival During Follow-up
-------------------------

Overall survival curves are given in Supplemental Digital Content Fig. S2, available at. One-year (365 days) Kaplan-Meier survival estimates (±standard error) were 77% ± 3% in PG and 76% ± 4% in PJ and thus comparable (*P* = 0.675 in 2-sided log-rank test) (see Supplemental Digital Content Fig. S2, available at).

Pancreatic Function and Long-term Follow-up
-------------------------------------------

The percentage of patients receiving oral enzyme replacement rose from 8% preoperatively to around 80% during 6- and 12-month follow-up. Exploratory analysis also suggested a significantly reduced rate of oral enzyme replacement therapy in patients with PG at 6 months after the operation (PG vs PJ, 72% vs 89%, *P* \< 0.001). This difference did not persist at 12-month follow-up because of a slightly decreasing percentage of PJ patients using oral enzyme supplementation (PG vs PJ, 72% vs 81%, *P* = 0.11). However, simultaneously the rate of patients reporting steatorrhea in the PJ group increased (from 17% at 6 months to 22% at 12 months), suggesting now insufficient enzyme supplementation in some patients. This was not the case with PG, where reported steatorrhea decreased from 20% to 13%. The amount of enzyme units taken per day was comparable in both treatment groups.

The prevalence of diabetes mellitus rose only slightly after pancreatoduodenectomy (from 25% at operation to 31% at 12-month follow-up) and was comparable after PG and PJ. Among diabetic patients, there was an increase of insulin dependence from around 50% to around 70% after pancreatoduodenectomy, whereas the percentage of patients with dietary therapy dropped only from 23% preoperatively to 13% and 9% at 6 and 12 months, respectively. There was no significant difference between both treatment arms (Table [4](#T4){ref-type="table"}).

Quality of Life and Long-term Follow-up
---------------------------------------

At the time of operation, EORTC QLQ-C30 and PAN26 scores were balanced between the treatment groups except for the physical functioning scale scores, which were higher in the PG group (*P* = 0.002). The patients assigned the lowest scores to role functioning and body image. Other major reported problems were fatigue, insomnia, pain, and digestive symptoms such as altered bowel habit. At 6 and 12 months after the operation, the most severe impairments were observed in role functioning, altered bowel habit, and fatigue. On the contrary, appetite, nausea, and hepatic symptoms improved. At 6 months, a reduced score on the financial problems scale could be observed (*P* = 0.044) in PG compared with PJ, which persisted at 12-month follow-up. Furthermore, emotional and social functioning scale scores were significantly better after PG than after PJ (*P* = 0.039 and 0.019) (see Supplemental Digital Content Table S5, available at).

DISCUSSION
==========

We report the currently largest RCT to compare PG and PJ in terms of POPF and perioperative complications and long-term outcome including quality of life. Of note, this multicenter trial was independently monitored. In contrast to previous RCTs, PG or PJ was not restricted to a specific subtype. The results of this trial have several implications for clinical practice. First, although it was designed to confirm the hypothesis of a reduction of clinically relevant POPF in patients with PG, the results show similar rates of grade B/C POPF regardless of the reconstruction method with an overall rate of 21%. This is higher than the reported range of 4% to 18% from large retrospective benchmark series (see Supplemental Digital Content Table S1, available at). The previous RCTs report fistula rates between 12% and 24% (see Supplemental Digital Content Table S1, available at). In comparison with the other RCTs, RECOPANC included the oldest patients (average 68 years vs 56--67 years in other RCTs) with the highest body mass index (average 25 vs 21--25 in other RCTs). Of note, RECOPANC is also the first RCT to report independent monitoring. Taken together, the observed POPF rate must be considered valid in view of an ageing general population with increased operative risk.

Also, overall in-hospital mortality of 6% and the 90-day mortality of 7% in this trial do not meet the usually cited 5% benchmark for pancreatoduodenectomy. It is above the reported range of 0.7% to 3.7% from current large-scale retrospective series (see Supplemental Digital Content Table S1, available at), whereas some RCTs report comparable perioperative mortality rates of 0% to 11% (see Supplemental Digital Content Table S1, available at). In agreement with a current study,^[@R41]^ our data highlight the relevance of 90-day mortality figures in pancreatic surgery. It seems appropriate to accept that clinically relevant fistula rates of 20% and perioperative mortality of more than 5% mirror clinical reality even in high-volume pancreatic surgery. A similar effect was observed in the distal pancreatectomy trial, which reported a pancreatic fistula rate after distal pancreatic resection more than twice as high as previously reported in several retrospective series.^[@R42],[@R43]^

Meta-analysis of the available RCTs^[@R19]--[@R26]^ incorporating data from this trial suggests no significant reduction in POPF rates (odds ratio: 0.66; 95% confidence interval: 0.43--1.01; *P* = 0.056) (see Supplemental Digital Content Table S6, available at for details). This stands in contrast to current meta-analysis.^[@R44]^

In a multivariate analysis, the single most important factor influencing POPF rates was the quality and texture of the organ. Soft pancreatic texture, as judged intraoperatively by the surgeon, has been demonstrated to bear a higher risk for secondary complications, erosion bleeding, and mortality in previous studies.^[@R6],[@R9],[@R11],[@R24],[@R37],[@R38],[@R40]^ It has been shown that subjective evaluation of the pancreatic hardness and texture strongly correlates with the histopathological degree of fibrosis.^[@R40]^ On the one hand, pancreatic cancer and chronic pancreatitis are usually associated with hardening of the whole organ including the pancreatic remnant; on the other hand, prophylactic surgery for benign lesions such as cystic neoplasms or small tumors such as ampullary cancer is usually associated with soft pancreatic tissue.^[@R9],[@R19],[@R40]^

As outlined, all participating clinics were high-volume academic centers for pancreatic surgery, and there was no statistically significant center effect regarding POPF rate. Nevertheless, a high odds ratio for POPF in the low-volume surgeons indicates that besides center volume, individual surgeon volume is a relevant factor influencing complication rates in pancreatoduodenectomy.

Furthermore, from our data, it might be speculated that PG offers an easier-to-learn technique suited for less experienced surgeons, but this effect did not reach statistical significance. This opinion has also been expressed by other authors of previous RCTs^[@R19],[@R20],[@R24],[@R26]^ on the basis of the assumption that it is technically easier to achieve secure invagination of the pancreatic remnant with PG, especially in case of a bulky soft pancreas. Reasons given for conversion to PG instead of PJ (soft pancreas in 11 of 12 cases) in the current trial may reflect this assumption. However, operation time was not reduced with PG in the current trial, and only 2 previous RCTs^[@R23],[@R26]^ found a shorter operation time with PG.

The incidence of grade A and B postpancreatectomy hemorrhages was increased after PG. By ISGPS definition, grade A bleeding has no therapeutic consequence, but grade B events require conservative or even invasive therapy and may be sentinels of later grade C hemorrhage. The feared life-threatening (grade C) bleeding events were not increased with PG. These findings confirm previous retrospective and prospective observations, which showed increased bleeding events from PGs.^[@R23],[@R45],[@R46]^ Meticulous hemostatic measures at the pancreatic cut surface are, therefore, advised. There was a higher rate of perioperative stroke events in patients with PGs that were not associated with the bleeding events, however. For lack of a rational explanation, this might be interpreted as an artifact of exploratory data analysis.

Our reported length of hospital stay (median, 16 days) is about twice as long as that usually reported from high-volume North American centers (see Supplemental Digital Content Table S1, available at). Our explanations are that due to law-enforced universal health care insurance in Germany, patients usually do not experience financial pressure to be discharged early, and the common practice is to discharge patients home after full recovery. Even in a fast-track surgery program applied to major pancreatic resections in a German center,^[@R47]^ patients were discharged at median on day 10, with a 30-day readmission rate of only 3.5%, whereas readmission rates of 15% to 20% after pancreatoduodenectomy are currently reported from the United States.^[@R48],[@R49]^ In consequence, readmission has been highlighted as a significant problem by American scientific studies and is financially penalized in the United States but not in Germany.^[@R47]--[@R51]^

The results of long-term pancreatic function follow-up in the current trial may be interpreted as suggestive of better exocrine function in patients with PG. However, pancreatic function was not measured directly but by means of the surrogate parameters oral enzyme supplementation and steatorrhea, and the drawback of exploratory data analysis must be kept in mind. Previous RCTs with smaller case numbers have reported inconsistent outcomes.^[@R25],[@R26]^ The current study represents the largest prospective evaluation of this issue and will be followed by a prospective long-term observation of the included patients. Regarding the usually encountered opinion that pancreatic function is worse after PG compared with PJ, our results suggest that this is not the case.

Only one previous retrospective study compared quality of life after pancreatoduodenectomy with PG and PJ and found no difference, but it was unbalanced with regard to the preoperative patient status.^[@R52]^ Follow-up in the present trial did not reveal differences between the treatment groups in most aspects covered by the EORTC QLQ-C30/PAN26 questionnaires. On the contrary, the few detected that differences are not large enough to be considered clinically relevant. We also interpret these as an artifact of explorative analysis of the many quality-of-life aspects. Our results, however, provide valuable data to identify major problems that impair the quality of life of patients before and after pancreatoduodenectomy: role functioning, altered bowel habit, and fatigue.

CONCLUSIONS
===========

In summary, this trial demonstrated several salient findings. Reconstruction by PG, when not restricted to a specific subtype and evaluated in a multicenter setting, did not reduce perioperative complications. Soft pancreatic tissue quality remains the most influential factor for POPF rate. PG may offer a technically less demanding but safe anastomotic technique. However, a higher rate of postoperative grade A/B hemorrhage was observed, advocating increased awareness toward hemostatic measures with PG. The rate of POPF remains substantial and is currently underestimated. Perioperative mortality can surpass the 5% margin even in the high-volume academic pancreatic surgery setting. Both may be attributed to extended indications for pancreatoduodenectomy in an ageing population. Quality of life in pancreatoduodenectomy patients is most severely impaired regarding role functioning and body image. The operation seems to ameliorate gastrointestinal and hepatic symptoms but does not improve fatigue and role functioning. Long-term exocrine pancreatic function after PG does not seem to be inferior to PJ.
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###### 

Patients, Baseline Parameters, and Operations

                                                          PJ              PG          Total                                
  ------------------------------------------------------- --------------- ----------- ------- ---------- ----- ----------- -------
  Total                                                   149             171         320     ---                          
                                                          Baseline Data                                                    
  Age, yr                                                 66              29--87      68      35--86     68    29--87      0.787
  Sex                                                                                                                      
   Male                                                   93              62%         95      56%        188   59%         0.214
   Female                                                 56              38%         67      44%        132   41%         
  BMI (kg/m^2^)                                           25              15--43      25      16--39     25    15--43      0.706
  Chronic pancreatitis                                    14              9%          14      8%         28    9%          
  Pancreatic adenocarcinoma                               98              66%         104     61%        202   63%         
  Ampullary adenocarcinoma                                11              7%          10      6%         21    7%          
  Indications                                             0.695                                                            
   CNP                                                    4               3%          8       5%         12    4%          
   NET                                                    2               1%          3       2%         5     2%          
   Other                                                  20              13%         32      19%        52    16%         
   Weight loss                                            89              60%         97      57%        186   58%         0.587
  Symptoms                                                                                                                 
   Pain                                                   79              53%         84      49%        163   51%         0.487
   Jaundice                                               72              48%         88      52%        160   50%         0.575
  Preop biliary drainage                                                                                                   
   ERD                                                    60              40%         61      36%        121   38%         0.396
   PTD                                                    4               3%          7       4%         11    3%          0.488
  History of acute pancreatitis                           20              13%         17      10%        37    12%         0.331
  Chronic pancreatitis                                    40              27%         45      26%        85    27%         0.915
  Prior abdominal surgery                                 69              46%         80      47%        149   47%         0.932
  Cardiac                                                 58              39%         68      40%        126   39%         0.878
  pulmonary                                               14              9%          19      11%        33    10%         0.615
  Comorbidities                                                                                                            
   Renal                                                  15              10%         15      9%         30    9%          0.692
   Hepatic                                                9               6%          10      6%         19    6%          0.942
   Ex-smoker                                              40              27%         33      19%        73    23%         0.074
   Active smoker                                          44              30%         42      25%        86    27%         
   Ex-alcohol abuse                                       17              11%         19      11%        36    11%         0.673
   Active alcohol abuse                                   16              11%         24      14%        40    13%         
  ASA                                                                                                                      
   I                                                      14              10%         18      11%        32    10%         
   II                                                     81              56%         86      52%        167   53%         
   III                                                    50              34%         61      37%        111   36%         0.881
   IV                                                     1               1%          2       1%         3     1%          
   NA                                                     3               2%          4       2%         7     2%          
  Medication                                                                                                               
   Glucocorticoids                                        4               3%          3       2%         7     2%          0.570
   Immunosuppressives                                     2               1%          1       1%         3     1%          0.483
   Analgesics                                             29              20%         45      26%        74    23%         0.147
   Somatostatin analog                                    2               1%          0       0%         2     1%          0.129
   Neoadjuvant cx                                         4               3%          3       2%         7     2%          0.570
   Neoadjuvant rx                                         2               1%          1       1%         3     1%          0.483
  Laboratory                                                                                                               
   Amylase \[U/L\]                                        51              13--360     58      9--536     56    9--536      0.168
   Creatinine (μmol/L)                                    61              15--328     62      37--519    62    156--519    0.581
   Bilirubin (μmol/L)                                     12              3--598      15      2--371     14    2--598      0.951
   C-reactive protein (mg/L)                              6               0--111      6       0--177     6     0--177      0.618
   Total protein (g/L)                                    70              44--558     71      55--85     70    44--558     0.442
   CA 19--9 (U/mL)                                        42              1--11,000   48      1--4,491   47    1--11,000   0.503
   Hemoglobin (mmol/L)                                    8               4--10       8       4--10      8     4--10       0.418
   Leukocytes (1000/mL)                                   7               3--18       7       3--19      7     3--19       0.436
   Thrombocytes (1000/mL)                                 260             95--569     270     37--625    268   37--625     0.926
                                                          Operations                                                       
  Surgeon experience[^\*^](#TF1-1){ref-type="table-fn"}                                                                    
   \<5                                                    29              20%         24      14%        53    17%         
   5--10                                                  50              34%         54      32%        104   33%         0.301
   \>10                                                   69              47%         92      54%        161   51%         
   NA                                                     1               1%          1       1%         2     1%          
   \<10                                                   13              9%          15      9%         28    9%          
  Surgeon volume[^†^](#TF1-2){ref-type="table-fn"}                                                                         
   10--25                                                 43              29%         49      29%        92    29%         
   \>25                                                   92              62%         106     62%        198   62%         0.999
   NA                                                     1               1%          1       1%         2     1%          
  Technique                                                                                                                
   PPPD                                                   121             81%         134     78%        255   80%         0.528
   Classic Whipple                                        28              19%         37      22%        65    20%         
   NA                                                     5               3%          11      6%         16    5%          
  LAD                                                                                                                      
   Standard                                               106             71%         124     73%        230   72%         0.331
   Extended                                               38              26%         36      21%        74    23%         
   Portal venous resection                                30              20%         29      17%        59    18%         0.465
   Additional organ resection                             39              26%         39      23%        78    24%         0.484
  Blood loss                                              500             0--4,800    500     0--3,500   500   0--4,800    0.581
  Intraoperative red blood cell transfusion                                                                                
   No                                                     132             89%         146     85%        278   87%         
   1                                                      3               2%          6       4%         9     3%          0.708
   2                                                      8               5%          13      8%         21    7%          
   \>2                                                    6               6%          6       6%         12    12%         
  Pancreatic texture                                                                                                       
   Hard                                                   62              43%         66      41%        128   42%         
   Soft                                                   83              57%         95      59%        178   58%         0.755
   NA                                                     4               3%          10      6%         14    4%          
  MPD diameter                                                                                                             
   Normal (≤3 mm)                                         78              55%         94      58%        172   56%         
   Dilated (\>3 mm)                                       64              45%         69      42%        133   44%         0.630
   NA                                                     7               5%          8       5%         15    5%          

*P* values derived from 2-sided χ^2^ test and Student *t* test.

^\*^Years of pancreatic surgery.

^†^Pancreatoduodenectomies per year.

ASA indicates American Society of Anesthesiologists; BMI, body mass index; CA, 19-9, Carbohydrate antigen 19-9; CNP, cystic neoplasm of the pancreas; cx, chemotherapy; ERD, endoscopic retrograde drainage; LAD, lymphadenectomy; MPD, main pancreatic duct; NA, not assessed; NET, neuroendocrine tumor; PPPD, pylorus preserving pancreatoduodenectomy; PTD, percutaneous transhepatic drainage; rx, radiotherapy.

###### 

Primary Endpoint Analysis

                 Univariate Analysis                          
  -------------- --------------------- ----------- ---------- -------
  All patients   320                   253 (79%)   67 (21%)   ---
  PJ             149                   116 (78%)   33 (22%)   0.617
  PG             171                   137 (80%)   34 (20%)   

                                        Multivariate Analysis                   
  ------------------------------------- ----------------------- ------- ------- -------
  PG vs PJ                              0.864                   0.495   1.507   0.607
  Age, yr                               0.988                   0.966   1.011   0.318
  Soft vs hard pancreatic texture       2.094                   1.145   3.827   0.016
  Center location (north vs south)      1.048                   0.58    1.896   0.876
  Surgeon volume 10--25 vs \>25 PD/yr   1.578                   0.822   3.029   0.863
  Surgeon volume \<10 vs \>25 PD/yr     2.801                   1.155   6.794   0.064

*P* values derived from 2-sided χ^2^ test (univariate) and binary logistic regression (multivariate). CI indicates 95% confidence interval; PD, pancreatoduodenectomy; POPF, postoperative pancreatic fistula grade according to the International Study Group for Pancreatic Surgery definition.

###### 

Perioperative Secondary Endpoint Analysis

                                                                           PJ      PG         Total                                   
  ------------------------------------------------------------------------ ------- ---------- -------- ---------- -------- ---------- -------
  Total                                                                    149     171        320      ---                            
  Operation time                                                           337     165--565   332      165--600   332      165--600   0.706
  DGE[^\*^](#TF3-1){ref-type="table-fn"} (delayed gastric emptying)                                                                   
   No                                                                      87      59%        107      63%        194      61%        
   Grade A                                                                 39      27%        44       26%        83       26%        
   Grade B                                                                 9       6%         14       8%         23       7%         0.301
   Grade C                                                                 12      8%         6        4%         18       6%         
   Missing                                                                 2                  0                   2                   
  PPH[^\*^](#TF3-1){ref-type="table-fn"} (postpancreatectomy hemorrhage)                                                              
   No                                                                      132     89%        135      79%        167      83%        
   Grade A                                                                 1       1%         9        5%         10       3%         
   Grade B                                                                 6       4%         16       9%         22       7%         0.023
   Grade C                                                                 10      7%         11       6%         21       7%         
  IA with IPC drainage                                                     19      13%        18       11%        37       12%        
  IA with OP drainage                                                      12      8%         15       9%         27       8%         0.814
  Other surgical complications                                                                                                        
   Relaparotomy completion                                                 27      18%        20       12%        47       15%        0.100
   Pancreatectomy                                                          9       6%         6        4%         15       5%         0.285
   Hepaticoenterostomy leak                                                5       3%         3        2%         8        3%         0.480
   Gastroenterostomy leak                                                  3       2%         6        4%         9        3%         0.511
   SSI                                                                     18      12%        20       12%        28       12%        1.000
  Systemic complications                                                                                                              
   Septic shock                                                            4       3%         6        4%         10       3%         0.672
   Respiratory failure                                                     8       6%         12       7%         20       7%         0.542
   Deep vein thrombosis                                                    1       1%         0        0%         1        0%         0.283
   Lung embolism                                                           2       1%         3        2%         5        2%         0.766
   Myocardial infarction                                                   1       1%         1        1%         2        1%         0.923
   Stroke                                                                  0       0%         5        3%         5        2%         0.035
   Missing                                                                 6                  7                   13                  ---
  Postoperative hospital stay (d)                                          16      3--129     15       5--208     16       3--208     0.404
  In-house mortality[^†^](#TF3-2){ref-type="table-fn"}                     8/148   5%         10/169   6%         18/317   6%         0.963
  90-d mortality[^‡^](#TF3-3){ref-type="table-fn"}                         7/143   5%         16/165   10%        23/308   7%         0.167

*P* values derived from 2-sided χ^2^ test, Student *t* test.

^\*^According to the International Study Group for Pancreatic Surgery (ISGPS) definition.

^†^Missing data (n = 3) excluded.

^‡^Censored cases (n = 12) excluded.

DGE indicates delayed gastric emptying; IA, intra-abdominal abscess; IPC, interventional percutaneous; OP, operative; PPH, postpancreatectomy hemorrhage; SSI, surgical site infection requiring invasive treatment.

###### 

Long-term Pancreatic Function

  Pancreatic Function                                                                               
  --------------------- ----------------------------- ----- ----- ----- ----- ----- ----- --------- --
  OP                    Total patients in follow-up   149   171   320   ---                         
                        Steatorrhea                   23    15%   21    12%   44    14%   0.414     
                        OES                           13    9%    14    8%    27    8%    0.863     
                        DM                            35    24%   45    26%   80    25%   0.560     
  6 mo                  Total patients in follow-up   122   143   265   ---                         
                        Steatorrhea                   21    17%   28    20%   49    19%   0.621     
                        OES                           108   89%   103   72%   211   80%   \<0.001   
                        DM                            38    31%   40    28%   78    29%   0.572     
  12 mo                 Total patients in follow-up   101   122   223   ---                         
                        Steatorrhea                   22    22%   16    13%   38    17%   0.092     
                        OES                           82    81%   88    72%   170   76%   0.114     
                        DM                            34    24%   35    29%   69    31%   0.424     

  Therapy Details                                                                                       
  ----------------- ----- ----------------------- ------- --------- ------- --------- ------- --------- -------
  OP                OES   Enzyme per day (kU)     120     75--195   98      60--170   120     60--195   0.375
                          Dietary therapy only    7/35    20%       11/45   24%       18/80   23%       0.637
                    DM    Oral antidiabetics      15/28   54%       20/34   59%       35/62   57%       0.678
                          Insulin therapy         15/28   54%       17/34   50%       32/62   52%       0.678
                          Insulin units per day   18      8--43     24      6--50     19      6--50     0.625
  6 mo              OES   Enzyme per day (kU)     95      25--320   78      25--320   80      25--320   0.751
                          Dietary therapy only    4/38    11%       6/40    15%       10/78   13%       0.555
                    DM    Oral antidiabetics      13/35   38%       12/34   35%       25/68   37%       0.801
                          Insulin therapy         24/34   71%       24/34   71%       48/68   71%       1.000
                          Insulin units per day   25      4--48     25      8--130    25      4--130    0.583
  12 mo             OES   Enzyme per day (kU)     90      25--300   95      40--250   90      25--300   0.678
                          Dietary therapy only    2/34    6%        4/35    11%       6/69    9%        0.414
                    DM    Oral antidiabetics      12/32   38%       13/31   42%       25/63   40%       0.719
                          Insulin therapy         23/32   72%       19/31   61%       42/63   67%       0.373
                          Insulin units per day   28      2--45     22      4--64     25      2--64     0.739

*P* values derived from 2-sided χ^2^ test and Student *t* test. DM indicates diabetes mellitus; OES, oral enzyme supplementation; OP, operation.
